G6PD1 Antibody

Introduction to G6PD1 Antibody

G6PD1 antibody is a research tool designed to detect and quantify glucose-6-phosphate dehydrogenase (G6PD), a cytosolic enzyme encoded by the X-linked G6PD gene . This enzyme catalyzes the first step of the pentose phosphate pathway (PPP), generating NADPH to maintain redox balance and support biosynthetic processes . G6PD1 antibodies are critical for studying G6PD function in oxidative stress response, immune regulation, and disease pathogenesis .

Applications in Research and Clinical Diagnostics

G6PD1 antibodies enable precise detection of G6PD in diverse biological contexts:

Validation Data:

• Proteintech’s 25413-1-AP antibody is cited in 40+ studies for WB, IHC, and ICC .

• Invitrogen’s MA5-15918 monoclonal antibody shows strong specificity in WB and ELISA .

Immune System Regulation

G6PD1 antibodies have elucidated G6PD’s role in immune cell function:

• Innate Immunity: G6PD-derived NADPH sustains phagocytic oxidative bursts in neutrophils and macrophages, crucial for pathogen clearance .

• Adaptive Immunity: G6PD activity regulates T-cell metabolism, cytokine production (e.g., IFN-γ), and glycolytic flux .

• Autoimmunity: G6PD deficiency correlates with increased autoimmune disease risk, including systemic lupus erythematosus (SLE) and rheumatoid arthritis .

Disease Associations

Hemolytic Risk Assessment

G6PD1 antibodies aid in identifying G6PD deficiency variants that predispose to hemolysis:

• Reference Intervals: Establishing activity thresholds helps predict hemolysis risk from oxidative triggers (e.g., primaquine, sulfonamides) .

• Monitoring: Post-diagnosis, antibodies track enzyme activity to guide avoidance of hemolytic agents .

Pharmacological Correction

• AG1 Compound: Small-molecule activator of G6PD mutants (e.g., Canton R459L) increases enzyme activity, reduces oxidative stress, and improves survival in zebrafish models .

• Mechanism: Stabilizes G6PD dimer structure and enhances PPP flux, restoring NADPH production .